Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $63.83 Average PT from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $63.83.

Several brokerages have recently commented on CLDX. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Wolfe Research started coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price target on the stock. Wells Fargo & Company upped their price objective on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus began coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors have recently bought and sold shares of CLDX. Price T Rowe Associates Inc. MD boosted its holdings in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after acquiring an additional 2,664,915 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Celldex Therapeutics by 126.9% in the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after buying an additional 2,030,013 shares during the period. Point72 Asset Management L.P. boosted its stake in Celldex Therapeutics by 105.3% during the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after buying an additional 1,413,722 shares in the last quarter. Wellington Management Group LLP grew its holdings in Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after acquiring an additional 1,044,728 shares during the period. Finally, Novo Holdings A S bought a new stake in Celldex Therapeutics in the second quarter worth about $31,458,000.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $40.17 on Thursday. The firm’s fifty day moving average price is $38.55 and its 200 day moving average price is $38.54. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -14.09 and a beta of 1.56. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Analysts forecast that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.